Bayer Aktiengesellschaft

Bayer Intellectual Property Gmbh

Other

Bayer Healthcare Aktiengesellschaft

Bayer Aktiengellschaft

Hanno Wild

Jens-Kerim Ergüden

Rainer Endermann

Peter Kolkhof

Kai Thede

Ingo Flamme

Felix Oehme

Joachim Schuhmacher

Dieter Habich

Bernd Riedl

Andreas Stolle

Hein-Peter Kroll

Klaus Schaller

Arnold Paessens

Mario Jeske

Friederike Stoll

Hartmut Beck

Harald Labischinski

Hans-Otto Werling

Klaus Dieter Bremm

Metin Akbaba

Jörg Keldenich

Jutta Hansen

Martin Ruppelt

Wolfgang Roeben

Siegfried Raddatz

Lars Bärfacker

Wolfgang Bender

Gunter Karig

Alexander Kuhl

Gerd Aichinger

Joachim Hütter

Dieter H Abich

Karl G Metzger

Johannes-Peter Stasch

Roger Astbury Smith

Hans-Georg Heine

Rudolf H Hanko

Klaus-Dieter Bremm

Ingo Haller

Jill E Wood

Thomas Krahn

Stephan Bartel

John E Lyons

Stefan Weigand

Robert B Dally

Wendy Lee

Walter Guarnieri

Michael B Katz

Daniel Harry Rogers

Hermann Wehlmann

Yolanda V Caringal

Michael Brands

Cheri Lynn Blum

Heiner Apeler

Wolfgang Roben

Jurgen Beunink

Michael Dorschug

Jorg Petersen-von Gehr

Wolfgang R Oben

Hans-Rudolf Pfaendler

Wolfgang Hartiwg

Christian Schröder

Jorg Lautz

Jorg Peters N-von Gehr

J Org Petersen-von Gehr

Stephen Bartel

Hans-Dietrich Horlein

The present application relates to novel substituted dihydropyrazolone derivatives, processes for their preparation, their use for treatment and/or prophylaxis of diseases and their use for the preparation of medicaments for treatment and/or prophylaxis of diseases, in particular cardiovascular and hematological diseases and kidney diseases, and for promoting wound healing.

Substituted dihydropyrazolones for treating cardiovascular and hematological diseases

The present application relates to novel dipyridyl-dihydropyrazolones, processes for their preparation, their use for treatment and/or prophylaxis of diseases and their use for the preparation of medicaments for treatment and/or prophylaxis of diseases, in particular cardiovascular and hematological diseases and kidney diseases, and for promoting wound healing.

4-(pyridin-3-yl)-2(pyridin-2yl)-1,2-dihydro-3H-pyrazol-3-one derivatives as specific HIF-pyrolyl-4-hydroxylase inhibitors for treating cardiovascular and haematological diseases

The present application relates to novel substituted dipyridyldihydropyrazolone derivatives, processes for their preparation, their use for treatment and/or prophylaxis of diseases and their use for the preparation of medicaments for treatment and/or prophylaxis of diseases, in particular cardiovascular and hematological diseases and kidney diseases, and for promoting wound healing.

Substituted dipyridyl-dihydropyrazolones and use thereof

Substituted dihydropyrazolones and use thereof as HIF-prolyl-4-hydroxylase inhibitors

Dipyridyl-dihydropyrazolones and their use

The invention relates to compounds of formula (I), to a method for the production thereof, and to the use of the same as pharmaceuticals for the treatment of diseases in humans and/or animals 

Substituted 2,5-diamidoindoles as ECE inhibitors for the treatment of cardiovascular diseases

Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se.

Inhibition of raf kinase activity using aryl ureas

hIL-4 mutant proteins used as antagonists or partial agonists of human

The invention relates to heteroatom-containing benzocyclopentaneoxazolidinones, to processes for their preparation and their use as medicaments, especially as antibacterial medicaments.

Heteroatom-containing benzocyclopentane-oxazolidinones

The present invention relates to heteroatom-containing cyclopentanopyridyl-oxazolidinones, processes for their preparation and their use as medicaments, in particular as antibacterial medicaments.

Heteroatom-containing cyclopentanopyridyl-oxazolidinones

The invention relates to 6-membered nitrogen-containing heteroaryloxazolidinones, processes for their preparation and their use as medicaments, in particular as antibacterial medicaments.

6-membered nitrogen-containing heteroaryl-oxazolidinones

The present invention relates to 5-membered heteroaryl-oxazolidinones, to processes for their preparation and to their use as medicaments, in particular as antibacterial medicaments.

5-membered heteroaryl-oxazolidinones

Growing community of inventors

Wuppertal, Germany

Hanno Wild